role etoposide management lymphomas Hodgkin disease Etoposide derivative epipodophyllotoxin important new drugs management malignant lymphomas past decade number specific protocols useful agent management malignant lymphoma time primary treatment relapse broad activity etoposide several histologic subtypes malignant lymphoma Hodgkin disease potential optimal doses schedules etoposide single-agent activity rivals drugs agents doxorubicin protein synthesis topoisomerase II inhibitor potential non-cross-resistant cytotoxicity brief comment single-agent activity etoposide report integration etoposide multiagent protocols primary treatment malignant lymphoma Hodgkin disease specific findings protocols prednisone methotrexate doxorubicin cyclophosphamide etoposide-cytarabine bleomycin vincristine methotrexate Pro-MACE-CytaBOM US National Cancer Institute NCI doxorubicin cyclophosphamide vincristine prednisone bleomycin VACOP-B Vancouver primary treatment malignant lymphoma vinblastine cyclophosphamide doxorubicin bleomycin vincristine prednisone VECABOP Vancouver treatment untreated patients advanced Hodgkin disease 